Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price & How to Invest
Short answer
Crinetics Pharmaceuticals (CRNX) is a commercial-stage endocrine-focused biotech whose lead drug PALSONIFY (paltusotine) is an FDA-approved once-daily oral acromegaly therapy, but as of July 2026 the investment picture is dominated by a definitive agreement for Vertex to acquire Crinetics for $85.00 per share in cash. That pending deal, expected to close in Q3 2026, means the stock now trades largely as a merger-arbitrage situation rather than a standalone growth story.
CRNX stock price
As of 2026-07-08, Crinetics Pharmaceuticals, Inc. (CRNX) last closed at $83.49, up 158.2% over the past year. Over the past 52 weeks it has traded between $26.85 and $83.53.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Crinetics Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Crinetics Pharmaceuticals, Inc. (CRNX) do?
Crinetics Pharmaceuticals is a San Diego-based biopharmaceutical company that discovers and develops oral small-molecule therapies for endocrine diseases and endocrine-related tumors. Its first marketed product, PALSONIFY (paltusotine), is a non-peptide, once-daily oral selective somatostatin receptor ligand approved by the FDA in September 2025 and by European regulators in 2026 for acromegaly, a condition long treated with monthly injectable drugs. Behind PALSONIFY sits a deep pipeline of 10-plus programs, led by atumelnant (in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome) and CRN09682, a drug conjugate aimed at neuroendocrine tumors, plus earlier programs across Graves' disease, hyperparathyroidism, polycystic kidney disease, and other endocrine indications.
The investment picture changed materially on July 6, 2026, when Vertex Pharmaceuticals agreed to acquire Crinetics for $85.00 per share in cash, valuing the equity at roughly $10 billion. The deal, unanimously approved by both boards, is not subject to a financing condition and is expected to close in the third quarter of 2026 subject to Crinetics shareholder approval and antitrust clearance. As a result, CRNX shares trade near the agreed price, and the standalone questions about PALSONIFY's launch ramp and pipeline readouts now matter mainly to the extent they affect whether and when the acquisition completes.
What's driving Crinetics Pharmaceuticals, Inc. (CRNX)?
1. Pending Vertex acquisition at $85 cash
Vertex agreed on July 6, 2026 to buy Crinetics for $85.00 per share in cash, about $10 billion in equity value, backed by $4.5 billion of committed bridge financing and no financing condition. Management guides to a Q3 2026 close, so the near-term stock behavior is driven by the probability and timing of that close rather than fundamentals. Any residual gap between the market price and $85 reflects the market's view of deal risk.
2. PALSONIFY commercial launch
PALSONIFY (paltusotine) is the first non-peptide once-daily oral option for acromegaly, replacing burdensome monthly injections. Early launch metrics showed roughly $10.3 million of net product revenue in Q1 2026 with 263 unique prescribers and about 70% of patients on reimbursed therapy. European approval and additional global filings extend the addressable market.
3. Deep endocrine pipeline
Beyond PALSONIFY, the pipeline includes late-stage atumelnant for congenital adrenal hyperplasia and Cushing's syndrome and CRN09682 for neuroendocrine tumors, plus discovery programs in Graves' disease, hyperparathyroidism, and polycystic kidney disease. This breadth is a large part of what attracted Vertex, which is expanding beyond its cystic fibrosis franchise. Successful readouts could add value inside the combined company.
4. Strong balance sheet as a standalone
Crinetics held about $1.3 billion in cash and investments as of March 31, 2026 after a January 2026 offering, funding operations for well beyond a year on a standalone basis. That cushion reduced the pressure to raise capital and gave the company negotiating strength. It also lowered the acquirer's net cost, with Vertex citing roughly $8.8 billion net of acquired cash.
What are the risks to Crinetics Pharmaceuticals, Inc. (CRNX)?
The dominant risk is deal risk: the Vertex acquisition still requires Crinetics shareholder approval, antitrust and other regulatory clearances, and satisfaction of customary closing conditions, and if it fails the stock could fall back toward its pre-announcement level near the $45 to $55 range implied by a roughly $4.5 billion market cap. On a standalone basis, Crinetics remains deeply unprofitable, posting a net loss of about $127.8 million in Q1 2026 against only $10.7 million of revenue, and PALSONIFY faces entrenched competition from injectable and oral incumbents. Clinical programs like atumelnant and CRN09682 carry the usual risk of trial failure or regulatory delay. Because the current price largely embeds the $85 cash offer, the upside from here is capped while the downside if the deal breaks is meaningful.
How is Crinetics Pharmaceuticals, Inc. (CRNX) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Crinetics Pharmaceuticals, Inc.'s investor relations page or your broker.
- Acquisition price (Vertex, cash): ~$85.00/share
- Deal equity value: ~$10B
- Revenue (Q1 2026): ~$10.7M
- PALSONIFY net product sales (Q1 2026): ~$10.3M
- Net loss (Q1 2026): ~$127.8M
- Cash and investments (Mar 31, 2026): ~$1.3B
Before the July 2026 acquisition announcement, Crinetics carried a market capitalization of roughly $4.5 billion despite minimal revenue, a valuation typical of a rare-disease biotech pricing in an early launch and pipeline optionality. The Vertex offer of $85.00 per share, about $10 billion in equity value, reset the stock to trade near that cash price. Standard earnings multiples are not meaningful here given the company runs a large net loss funded by its cash balance.
Who competes with Crinetics Pharmaceuticals, Inc. (CRNX)?
Injectable somatostatin analog incumbents
Ipsen (Somatuline Depot), Novartis (Sandostatin/octreotide), and Camurus (octreotide long-acting) dominate the established acromegaly market with monthly injectable therapies. PALSONIFY competes by offering a once-daily oral alternative that reduces injection burden.
Other oral and second-line acromegaly drugs
Chiesi's MYCAPSSA (oral octreotide capsules) is the prior oral entrant, approved as maintenance for responders, while Pfizer's SOMAVERT (pegvisomant) serves patients refractory to somatostatin ligands. These set the direct benchmark for paltusotine's efficacy and convenience positioning.
Large-cap rare-disease and endocrine pipelines
Vertex, the acquirer, along with peers like Ascendis Pharma and other endocrine-focused biotechs, compete for the same rare-disease patient populations and pipeline assets. The acquisition folds Crinetics into Vertex's push to diversify beyond cystic fibrosis.
How to invest in Crinetics Pharmaceuticals, Inc. (CRNX)
There are three common ways to get CRNX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CRNX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where CRNX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Crinetics Pharmaceuticals, Inc. (CRNX)
CRNX has shifted from a rare-disease biotech growth thesis to a pending-buyout name, with its remaining value tied to whether Vertex's $85-per-share cash acquisition closes as planned.
More on Crinetics Pharmaceuticals, Inc. (CRNX)
Whether CRNX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRNX a buy?, and where the stock could go from here in the CRNX stock forecast.
For income investors, whether CRNX pays a dividend and how the payout looks is covered in does CRNX pay a dividend?
Build a basket around CRNX with Walnut
Use Crinetics Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Crinetics Pharmaceuticals do?
+
Crinetics develops oral small-molecule therapies for endocrine diseases and endocrine-related tumors. Its lead product, PALSONIFY (paltusotine), is a once-daily oral treatment for acromegaly, and it has a pipeline of additional programs including atumelnant for congenital adrenal hyperplasia and Cushing's syndrome.
Why is CRNX in the news in 2026?
+
On July 6, 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $85.00 per share in cash, valuing the company at roughly $10 billion. The deal is expected to close in the third quarter of 2026, so CRNX now trades largely as a pending-acquisition name.
What is PALSONIFY (paltusotine)?
+
PALSONIFY is Crinetics' non-peptide, once-daily oral selective somatostatin receptor ligand for acromegaly. The FDA approved it in September 2025 and European regulators approved it in 2026, positioning it as an oral alternative to established monthly injectable therapies.
Is Crinetics profitable?
+
No. As of Q1 2026 the company reported a net loss of about $127.8 million against roughly $10.7 million of revenue, as it invests heavily in launching PALSONIFY and advancing its pipeline. It funds these losses from a cash balance of about $1.3 billion as of March 31, 2026.
What are the risks around CRNX right now?
+
The main risk is that the Vertex acquisition fails to close, which could push shares back toward pre-announcement levels. Standalone risks include continued large net losses, competition in acromegaly from injectable and oral incumbents, and the possibility of clinical trial setbacks in the pipeline.
Who competes with Crinetics in acromegaly?
+
Established players include Ipsen (Somatuline), Novartis (Sandostatin/octreotide), and Pfizer (Somavert), plus Chiesi's oral MYCAPSSA and Camurus' long-acting octreotide. PALSONIFY differentiates itself as a once-daily oral non-peptide option.
How can I follow how CRNX is doing?
+
You can track CRNX through its price relative to the $85 cash offer, deal-related news on shareholder and regulatory approvals, and PALSONIFY launch metrics like revenue and prescriber counts. Walnut is not an investment adviser, so treat any figures here as descriptive and do your own research.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Crinetics Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.